Compare FTAI Aviation Ltd (FTAI) vs Novavax Inc (NVAX) Price & Performance

FTAI Aviation trades at $226.66, up 0.47% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a 15.94% net margin and 167.93% ROE, but valuation ratios are elevated (P/E 49.49, P/S 7.59). Recent Q2 2026 earnings missed estimates at $1.13 per share, and the company announced a strategic shift toward asset-light management and a new $0.50 dividend.

Outlook is mixed: robust analyst consensus (18 buys, $341.67 target) and power segment growth offer upside, but earnings misses, high leverage, and declining cash flow pose risks. The stock's premium valuation requires execution on guidance and margin improvement to justify further gains.

Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.

The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.